/clinical/,/clinical/tools-resources/,/clinical/tools-resources/lab-test-directory/,/clinical/tools-resources/lab-test-directory/chemistry/,

/clinical/tools-resources/lab-test-directory/chemistry/name-69036-en.labtest

Nov 11, 2015

page

100

UWHC,UWMF,

Clinical Hub,Tools & Resources,UWHC Lab Test Directory,Chemistry

PSA Total, Diagnostic with Reflex to Free PSA

PSA Total, Diagnostic with Reflex to Free PSA (HCPSADRF) Chemistry Lab Test

Name: PSA Total, Diagnostic with Reflex to Free PSA

Test Name: PSA Total, Diagnostic with Reflex to Free PSA

Health Link Test Code: HCPSADRF

LIS Test Code: PSADRF

CPT Code(s): 84153; if reflexed to Free PSA add cpt 84154

Test Component:

For patients 50 years of age and older:

Total PSA, and Free PSA if Total PSA is between 4.00 ng/mL and 10.00 ng/mL.

 

For patients <50 years of age:

Total PSA, and Free PSA if Total PSA is between 2.50 ng/mL and 10.00 ng/mL.

Methodology: Chemiluminescent Immunoassay

Days Performed: Daily, 24 hours.

In-Lab Turnaround Time: 4 hours.

Stat In-Lab Turnaround Time: 1 hour.

Specimen: Blood

Collection Container: Red cap with yellow ring (SST)

Also Acceptable: Red top

Collection Volume: 2 mL

Pediatric Collection Volume: 1 mL

Stability Refridgerated:

24 hours

Stability Frozen:

>24 hours

Sample Analyzed: Serum

Testing Volume: 0.3 mL

Pediatric Testing Volume: 0.15 mL

Specimen Processing:

Centrifuge within 2 hours of collection. If a complete barrier has not formed, transfer cell-free serum to plastic vial. Refrigerate.

Specimen Transport:

Transport specimen to UWHC Hospital Laboratory. Transport with coolant pack if coming from clinic location. Send frozen if sample will be more than 48 hours old when it arrives.

Interpretation:

PSA Total, Diagnostics Reference Interval:

18 years and up:  0.00-4.00 ng/mL

 

PSA, % Free Interpretive Guidelines:

 

Both total and free PSA determinations were performed at UW Hospital & Clinics using the Abbott Architect i2000. The free PSA percentage is an aid in distinguishing prostate cancer from benign prostatic conditions in men ages 50 and older with a total PSA between 4.0 and 10.0 ng/mL.  Numerous studies have shown that the % free PSA is generally lower in prostate cancer than in benign prostatic hypertrophy (BPH).  Abbott suggests that a cutoff of 26% or less free PSA (i.e. perform a biopsy at or below this cutoff) yields a sensitivity of 91.1% and specificity of 18.2% in discriminating prostatic cancer from BPH.

 

Interpretation Type: Reference Interval

Test Limitations:

Samples should be obtained before biopsy, prostatectomy or prostatic massage, since manipulation of the prostate gland may lead to elevated PSA levels persisting for up to 3 weeks.

 

Studies have shown conflicting results on the existence of an effect of digital rectal examination on PSA level. Therefore, when possible, obtain PSA samples before digital rectal examination.

 

PSA expression may be altered due to hormonal therapy for prostate cancer. Consequently, a low PSA result following a prostatic cancer treatment which includes hormonal therapy may not adequately reflect the presence of residual or recurrent disease.

 

Results may be affected if patient has developed Human Anti-Murine Antibodies (HAMA) due to exposure to murine based products.

 

Heterophilic antibodies in human serum can react with the immunoglobulins included in the assay components causing interference with in vitro immunoassays. Samples from patients routinely exposed to animals or animal serum products can demonstrate this type of interference potentially causing an anomalous result.

Additional Information:

The PSA assay may be used in conjunction with a digital rectal exam as a screening test for prostate cancer.